A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

Gynecologic Oncology

Volumn 70, Issue 3, 1998, Pages 404-409

  Gershenson, David M ^a   Burke, Thomas W ^a   Morris, Mitchell ^a   Bast, Robert C ^a   Guaspari, Al ^b   Hohneker, John ^b   Wharton, J Taylor ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Chemotherapy; Ovarian cancer; Vinorelbine

Indexed keywords

NAVELBINE; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032168461     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5130     Document Type: Article

References (24)

1. Parker S L, Tong T, Bolden S, Wingo P A. Cancer statistics, 1997. CA Cancer J Clin. 47:1997;5-27.
2. Langlois N, Gueritte F, Langlois Y, Potier P. Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloid. J Am Chem Soc. 22:1976;7017-7024.
3. Mathe G, Reizenstein P. Phase I pharmacologic study of a new vinca alkaloid: Navelbine. Cancer Lett. 27:1985;285-293.
4. George M J, Heron J F, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, Guastalla J P, Namer M, Bugat R, Ayme Y. Navelbine in advanced ovarian epithelial cancer: a study of the French Oncology Centers. Semin Oncol. 16:1989;30-32.
5. Bajetta E, Di Leo A, Biganzoli, Mariani L, Cappuzzo F, Bartolomeo M D, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 14:1996;2546-2551.
6. Blessing J A. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. Chemotherapy of Gynecologic Cancer. 1990;Wiley-Liss, New York. p. 63-97.
7. Statview 4.5 Software Program, Berkeley, CA, Abacus Concepts, 1995.
8. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin J C. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol. 14:1991;115-119.
9. Berthaud P, Le Chevalier T, Ruffie P, Baldeyrou P, Arriagada R, Besson F, Tursz T. Phase I-II study of Navelbine (vinorelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 28A:1992;1863-1865.
10. O'Rourke M, Crawford J, Schiller J, Laufman L, Yanovich S, Ozer H, Langleben A, McGill U, Barlogie B, Koletsky A, Clamon G, Purvis J, Tuttle R, Hohneker J. Survival advantage for patients with stage IV NSCLC treated with single agent vinorelbine in a randomized controlled trial. Proc Am Soc Clin Oncol. 12:1993;343.
11. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi R B, Ambrosini G. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol. 12:1994;2094-2101.
12. Toussaint C, Izzo J, Spielmann M, Merle S, May-Levin F, Armand J P, Lacombe D, Tursz T, Sunderland M, Chabot G G, Cvitkovic E. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol. 12:1994;2102-2112.
13. Weber B L, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 13:1995;2722-2730.
14. Morris M, Burke T, Levenback C, Wharton J T, Gershenson D. Phase II study of vinorelbine in advanced squamous carcinoma of the uterine cervix (SCC): preliminary results. Proc Am Soc Clin Oncol. 14:1995;268.
15. Lavaca J A, Leone B A, Machiavelli M, Romero A O, Pérez J E, Elem Y L, Ferreyra R, Focaccia G, Suttora G, Salvadori M A, Cuevas M A, Acuña L R, Acuña J R, Langhi M, Amato S, Castaldi J, Arroyo A, Vallejo C T. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol. 15:1997;604-609.
16. Pinon G, Pinel M C, Goudier M J, Coiffier B, Filippi M H, Goupil A, Roullet B, Facchini T, Mignot L, Tresca P. Etude de la vinorelbine associee a l'hexamethylmelamine dans les adenocarcinomes de l'ovaire: Resultats d'un essai phase I-IIA, NH0-88, du groupe "ovaire" de l'ARTAC. Bull Cancer. 78:1991;1119-1131.
17. Romero A, Rabinovich M G, Vallejo C T, Perez J E, Rodriguez R, Cuevas M A, Machiavelli M, Lacava J A, Langhi M, Acuña L R, Amato S, Barbieri R, Sabatini C, Leone B A. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 12:1994;336-341.
18. Crawford J, O'Rourke M, Schiller J H, Spiridonitis C H, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 14:1996;2774-2784.
19. Rittenberg C R, Gralla R J, Rehmeyer A T. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum. 22:1995;707-710.
20. Havlin K, Lucas S, Guaspari A, Hohneker J, Winer E. Phase I/II study of daily ×3 navelbine with an attempt at dose-escalation with filgrastim in metastatic breast cancer. Proc Am Soc Clin Oncol. 15:1996;122.
21. Livingston R B, Ellis G K, Gralow J R, Williams M A, White R, McGuirt C, Adamkiewicz B B, Long C A. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 15:1997;1395-1400.
22. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
23. Adams D J. Synergy of Navelbine-Taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res. 35:1994;327.
24. Knick V C, Eberwein D J, Miller C G. Preclinical activity of Navelbine and Taxol drug combinations. Proc Am Assoc Cancer Res. 35:1994;327.